Study Design: Retrospective database review.
Introduction
Back and neck pain are significant contributors to morbidity and health care costs in the United States. 1, 2 Many patients fail the first-line treatment of non-surgical interventions and proceed to surgical treatment. Cervical arthrodesis has evolved as a treatment for neck pain caused by disc disease and herniated discs that result in bony fusion of spinal segments. Cervical arthrodesis has been associated with a complication rate of about 3.9%, increasing with patient age. 3 These complications include infections, swallowing problems and dysphagia, neurological problems, and failure of bony fusion, which can lead to pain, instability, and require revision surgery.
Bone morphogenetic protein-2 (BMP) was approved by the US Food and Drug Administration (FDA) in 2002 to promote fusion in anterior lumbar surgery. 4 The use of BMP has increased from 2002 to 2011 with off-label applications accounting for the majority of use. 5 One of these off-label uses is in the cervical spine to increase bone growth and bony fusion while decreasing risk of pseudarthrosis and nonunion. 6 Over time, concerns have been raised regarding complication rates and safety, including a public health notification from the US FDA in 2008. [7] [8] [9] This study was conducted to examine the use of BMP in anterior cervical discectomy and fusion (ACDF) in the Medicare population and to determine risk of complications and associated costs within 90 days of surgery. We hypothesized that the use of BMP would increase complication rates and increase costs associated with care. As has previously been documented, we hypothesized that safety concerns regarding use of BMP would have a dramatic effect on its use for ACDF. We attempted to quantify the impact of these concerns on clinical utilization.
Methods
Records for patients who underwent ACDF were collected using the PearlDiver Patient Record Database (PearlDiver Technologies, Warsaw, IN). This is a publicly available national database of Medicare insurance records. Patients were identified by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. We performed a retrospective review over 48 million patients from January 1, 2005 through December 31, 2011. Region was defined as Midwest, Northeast, South, and West (Table 1) . Charges were calculated as amount billed by the institution for each patient for care surrounding the index procedure. Our institutional review board deemed this study exempt from review, as all patient information was deidentified. Incidence was calculated as procedures per 100 000 members. P values less than .05 were considered significant. Patient data was completely deidentified therefore did not require institutional review board approval.
Patients were eligible if they had ACDF from January There were differences among BMP use according to sex, age, and region ( (Table 3) . Averages charges for ACDF with BMP ($61 838) were significantly higher than those without BMP ($57 245) (P < .0001) ( Table 4 ). There were significant differences in costs for the BMP and non-BMP in every demographic subgroup with the exception of patients aged older than 84 years. ACDF charges were significantly higher for males compared with females without and with BMP use ($62 302 and $73 913 compared with $52 811 and $60 552, P < .001). Charges for both groups increased over time (Figure 2 $93 532 for a difference of $25 842. The differences remained significant throughout P < .0001.
Discussion
This data shows that the rate of use of BMP in ACDF in the Medicare population increased from 2005 to 2007 and then decreased thereafter. By 2011, BMP was being used in just over 12% of ACDF's in this population. This trend temporally matches the US FDA Public Health Notification indicating "life-threatening complications associated with BMP in cervical spine fusion," which was released in 2008. 9 This announcement, in addition to a growing body of literature warning against potential adverse effects of BMP, including radiculitis, soft-tissue swelling, dysphasia, heterotopic ossification, hematoma, seroma, and cancer may have led to this decrease in utilization. 3, 6, 7, 10 This decrease in BMP use is consistent with other trends of physician use following the US FDA advisory. 11 Still, utilization of 12% four years after the announcement is potentially concerning given the known serious adverse effects. Further study as to what the utilization and complication rate today are warranted.
We found that BMP utilization in ACDF to be highest in the Western region followed by Midwest, South, and Northeast. Overall use was lowest in the Northeast. Lao et al 12 found similar results; that BMP use in single level anterior interbody fusion was highest in the West and lowest in the Northeast. Singh et al 5 reported that overall BMP use in all spine surgery was highest in the South and lowest in the Northeast. Use of BMP was highest in the 70-to 74-year-old age group and least in the >84-year-old group. The lower use in the older age group may be due to the fact that these patients likely have lower life expectancy compared with younger patients; therefore, lifetime risk of pseudarthrosis, which BMP would help prevent, is decreased. It is unclear why the 70-to 74-year-old patients would have the highest rate of BMP use. Women were more likely to receive BMP, as has been found in other studies. 7 This may be because of women, especially elderly women, having lower bone density than men, 13, 14 which creates greater concern for pseudarthrosis. The rate of overall complications for ACDF was higher with BMP than without, consistent with many other studies. 8, 15 Our data indicated that wound complications occurred at a higher rate for patients treated with BMP than without (0.98% vs 0.76%). It is unclear whether this is due to BMP itself or selection bias of patients who had BMP used on them. Patients with risk factors suggestive of poor healing may be more likely to receive BMP. Our data regarding dysphagia/hoarseness did not show a statistically meaningful difference. Studies on this topic have had conflicting results. Lu et al 16 demonstrated that use of BMP2 increases severity of dysphasia while not affecting overall incidence of dysphasia. Singh et al 17 concluded a systematic review of the literature in 2014 and concluded that that rates of dysphagia were not affected by BMP. Several other studies have found a higher dysphasia rate with use of BMP. 18, 19 In 2011, Carragee et al 18 published the under reporting of adverse events related to BMP use in clinical trials, which had been underreported. Our data contributes to the growing body of literature that use of BMP contributes to perioperative morbidity and suggest that use of BMP is decreasing.
The differences in costs are not fully explained by the higher cost of BMP as the magnitude of the difference is much larger than the cost of BMP. Therefore, other factors such as increased complication rate probably contribute to the difference in cost. It is possible surgeons chose to used BMP in patients in with higher risk of complications. Our data shows that the >84-year-old age group, whom presumably would be a higher risk group for medical comorbidities did not have a significant cost differences. This is an area for further study. While charges increased for both groups over time, the difference between the 2 groups increased from $13 528 to $25 842, almost doubling, for reasons that are unclear.
There are several limitations to this study. The study is retrospective and based on medical coding, therefore subject to billing and coding errors. In addition, although it encompasses a large database, the Medicare population is not necessarily representative of the population at large. The <65-year age group covered by Medicare is a special population with end-stage renal disease or severe disability, therefore may be predisposed to risks compared with the >65-year group Medicare population who qualify for coverage based on age alone. 20 Our complication outcomes were not risk adjusted, therefore we were not able to identify whether patients who had BMP used were at inherently higher risk of complications. Other specified complication of procedure, not elsewhere classified Other specified complication Unspecified complication of procedure, not elsewhere classified Other and unspecified complication of medical care, not elsewhere classified
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